Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies

Mov Disord. 2011 Nov;26(13):2422-7. doi: 10.1002/mds.23863. Epub 2011 Jul 13.

Abstract

Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome.

Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients.

Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases.

Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Antiphospholipid / biosynthesis*
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / immunology
  • Antiphospholipid Syndrome / physiopathology*
  • Antipsychotic Agents / therapeutic use
  • Arteries / physiopathology
  • Child
  • Chorea / drug therapy
  • Chorea / immunology*
  • Chorea / physiopathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Lupus Erythematosus, Systemic / immunology*
  • Lupus Erythematosus, Systemic / physiopathology*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk
  • Steroids / therapeutic use
  • Thrombosis / immunology
  • Thrombosis / physiopathology
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Antiphospholipid
  • Antipsychotic Agents
  • Steroids